Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 15/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.52 |
| ▸ | ATP4A | P20648 | 2/20 | 0.47 |
| ▸ | ATP4B | P51164 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2169516 | 0.91 | LTA4H (1.00) | LTA4HKCNH2TLR9ATP4AATP4B | |
| SCHEMBL2168051 | 0.91 | LTA4H (0.95) | LTA4HKCNH2TLR9ATP4AATP4B | |
| SCHEMBL2168424 | 0.89 | LTA4H (1.00) | LTA4HKCNH2TLR9ATP4AATP4B | |
| SCHEMBL2170316 | 0.89 | LTA4H (1.00) | LTA4HKCNH2TLR9ATP4AATP4B | |
| SCHEMBL2168507 | 0.88 | LTA4H (1.00) | LTA4HKCNH2TLR9 | |
| SCHEMBL6365156 | 0.87 | LTA4H (0.80) | LTA4HKCNH2TLR9ATP4AATP4B | |
| SCHEMBL2168682 | 0.85 | LTA4H (1.00) | LTA4HKCNH2TLR9ATP4AATP4B | |
| SCHEMBL2167826 | 0.85 | LTA4H (0.80) | LTA4HKCNH2TLR9 | |
| SCHEMBL2170260 | 0.84 | LTA4H (1.00) | LTA4HKCNH2TLR9 | |
| SCHEMBL2168554 | 0.84 | LTA4H (0.77) | LTA4HKCNH2TLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660491-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| US-20050043379-A1 | LTA4H Modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| WO-2005012296-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043379-A1 | LTA4H Modulators | LTA4H, LTB4R, LTB4R2 | LTA4H 1/4885KCNH2 3429/4885TLR9 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.